ASSESSMENT OF SILENT MYOCARDIAL ISCHEMIA (SI) IN PATIENTS WITH RENAL PARENCHYMA DERIVED HYPERTENSION (RDH) AND ITS PREDICTIVE VALUE FOR ACUTE CORONARY SYNDROMES (ACS)

2004 ◽  
Vol 22 (Suppl. 2) ◽  
pp. S218
Author(s):  
A. Papadogiannakis ◽  
D. Xydakis ◽  
M. Sfakianaki ◽  
K. Papachristoforou
2017 ◽  
pp. 59-63
Author(s):  
Thanh Hung Dieu ◽  
Anh Vu Nguyen

Objects: We assessed the ability of ST-segment elevation in lead aVR to predict left main and/or 3-vessel disease (LM/3VD) in patients with acute coronary syndromes (ACS). Meterial and Method: 410 patients with ACS, who underwent coronary angiography, were evaluated. Results: 131 (31.9%) patients have been LM/3VD. ST segment elevation > 0.05 mV in leads aVR have been an independent predictor LM/3VD with sensitivity, specificity, positive predictive value PPV) and negative predictive value (NPV) 74.0%, 78.1%, 61.4% and 86.5%, respectively (p<0.001). ST segment elevation > 0.05 mV in leads aVR with ST segment depression in leads V4-V6 have related LM/3VD with sensitivity, specificity, PPV and NPV 44.3%, 92.8%, 74.4% and 75.2%, respectively (p<0.001). ST segment elevation > 0.1 mV in leads aVR have related LM/3VD with sensitivity, specificity, PPV and NPV 51.9%, 87.1%, 65.1% and 79.4%, respectively (p<0.001). Conclusions: ST segment elevation > 0.05 mV in leads aVR have been an independent predictor LM/3VD in patients with ACS. Key words: Acute coronary syndromes, ST-segment elevation, aVR


CJEM ◽  
2006 ◽  
Vol 8 (01) ◽  
pp. 27-31 ◽  
Author(s):  
Giuseppe Lippi ◽  
Martina Montagnana ◽  
Gian Luca Salvagno ◽  
Gian Cesare Guidi

ABSTRACTThe diagnostic approach to acute coronary syndromes (ACS) remains one of the most difficult and controversial challenges facing emergency physicians. In recent years, cardiac troponins have emerged as the biochemical “gold standard” for diagnosis of patients with acute chest pain, enhancing our ability to recognize ACS. Early diagnosis and treatment of myocardial ischemia improve patient outcomes, but conventional markers are often nondiagnostic at the time of arrival at the emergency department. Promising new biomarkers, which appear earlier after the onset of ischemia, are being studied and integrated into clinical practice. Some are markers of myocyte necrosis, but others, including ischemia-modified albumin and natriuretic peptides, detect myocardial ischemia and myocardial dysfunction. The aim of the present article is to review the diagnostic approach to ACS, focusing on recent literature describing novel biochemical markers. If ongoing and future studies confirm their role in probability-based models risk assessment, a new era in the diagnostic approach to ACS may be dawning.


2002 ◽  
Vol 143 (1) ◽  
pp. 70-75 ◽  
Author(s):  
Michael C. Kontos ◽  
Joseph P. Ornato ◽  
Kristin L. Schmidt ◽  
James L. Tatum ◽  
Robert L. Jesse

2017 ◽  
Vol 70 (18) ◽  
pp. B195-B196
Author(s):  
Barbara Stähli ◽  
Philipp Jakob ◽  
Roland Klingenberg ◽  
Slayman Obeid ◽  
Dik Heg ◽  
...  

Diabetes Care ◽  
2001 ◽  
Vol 24 (2) ◽  
pp. 339-343 ◽  
Author(s):  
P. Valensi ◽  
R.-N. Sachs ◽  
B. Harfouche ◽  
B. Lormeau ◽  
J. Paries ◽  
...  

2010 ◽  
Vol 31 (2) ◽  
pp. 154-164 ◽  
Author(s):  
Adriano Caixeta ◽  
Gregg W. Stone ◽  
Roxana Mehran ◽  
Edwin A. Lee ◽  
Brent T. McLaurin ◽  
...  

2015 ◽  
Vol 125 (7-8) ◽  
pp. 545-552
Author(s):  
Marek Kiliszek ◽  
Anna Szpakowicz ◽  
Krzysztof J. Filipiak ◽  
Łukasz Kołtowski ◽  
Dominika Południewska ◽  
...  

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Amar M Salam ◽  
Khalid AlHabib ◽  
Wael Almahmeed ◽  
Alawi Alsheikh-Ali ◽  
Kadhim Sulaiman ◽  
...  

OBJECTIVES: It is well recognized that cardiac autonomic neuropathy associated with diabetes mellitus (DM) can cause silent myocardial ischemia, however there is limited research examining how the cardiac symptoms reported by patients with DM presenting with acute coronary syndromes (ACS) can affect the immediate and long term outcomes. The aim of the current study was to examine the prognostic impact of lack of chest pain symptoms in DM patients presenting with ACS and enrolled in a multicenter multinational ACS registry from the Middle East. METHODS: For a period of 9 months in 2008 to 2009, 7,930 consecutive patients with ACS were enrolled from 65 hospitals in 6 Middle East countries. A cohort of 3135 patients with DM were selected of whom 2686 (85.7%) presented with chest pain while 449 patients (14.3%) had no chest pain. Clinical features and outcomes were examined and compared among the two groups. RESULTS: Diabetic patients without chest pain were 5 years older and had significantly higher rates of hypertension (76.1% vs. 63.2%), prior myocardial infarction (35.9% vs. 24.3%), chronic kidney disease (CKD) (17.1% vs. 5.9%) and had significantly higher GRACE risk scores (55.3% vs. 21.4%) at presentation compared to patients with chest pain [All P <0.001]. Covariates independently associated with lack of chest pain in DM patients were; higher Killip class on presentation (OR, 6.2 [95%CI, 4.80-7.88]), female gender (OR, 1.50 [95%CI, 1.14-1.96]), CKD (OR, 1.8 [95%CI, 1.27-2.61]), tachycardia (OR, 2.50 [95%CI, 1.94-3.19]) and advanced age (OR, 1.03 [95%CI, 1.02-1.04]), [All P =0.001]. DM patients without chest pain had a significantly higher in-hospital and 1-year mortality rates (11.4% vs. 3.8%, P =0.001, and 25.7% vs. 12.2%, P =0.001, respectively). Lack of chest pain was an independent predictor of in-hospital and one year mortality (OR, 3.05 [95%CI, 2.05-4.54], P =0.001, and OR, 2.0 [95%CI, 1.52-2.75], P =0.001, respectively). CONCLUSIONS: DM patients with ACS presenting without chest pain are at an increased risk of immediate and long term mortality. Understanding the factors associated with atypical presentations of ACS in patients with DM may help in the earlier detection and more appropriate management of these high risk patients.


Sign in / Sign up

Export Citation Format

Share Document